Mel Rothberg, B.E., M.B.A. - Chief Operating Officer
Mel Rothberg is Chief Operating Officer of VGTI Florida. He is responsible for all administrative activities at the institute including finance, human resources, core scientific operations, institutional and business development, technology transfer, facility and incubation activities.
Mr. Rothberg brings more than 40 years of experience to VGTI as a national and international business executive from companies such as, Viragen, Inc., Althin Medical Inc., CD Medical Inc. (Dow Chemical), Cordis Dow Corporation and Goodyear. He has extensive international experience in all major markets with a particular emphasis in Europe and the Far East.
His executive management expertise includes operations, manufacturing, marketing, sales, distribution, research, licensing, finance and economic evaluation, and business development for the hemodialysis, cardiovascular, infectious disease, software and oncological markets.
In addition to his operational leadership, Mr. Rothberg has been responsible for and developed strategic business partnerships, infrastructure agreements, merger/acquisition agreements and international distribution agreements. He has successfully negotiated numerous contracts, technology licensing and business acquisition agreements. He has served as a board member for both publicly traded and privately held U.S. based companies and several foreign-based companies.
Mr. Rothberg also has extensive experience in the South Florida life science industry as a business development executive in the medical device, software and bio-pharmaceutical markets. He is presently on the Board of BioFlorida, the state’s life science trade industry group and serves as co-Chair of its southeast chapter.
Mr. Rothberg holds a Bachelor of Engineering in Chemical Engineering from Vanderbilt University and a Masters of Business Administration from Nova University.
Mr. Rothberg brings more than 40 years of experience to VGTI as a national and international business executive from companies such as, Viragen, Inc., Althin Medical Inc., CD Medical Inc. (Dow Chemical), Cordis Dow Corporation and Goodyear. He has extensive international experience in all major markets with a particular emphasis in Europe and the Far East.
His executive management expertise includes operations, manufacturing, marketing, sales, distribution, research, licensing, finance and economic evaluation, and business development for the hemodialysis, cardiovascular, infectious disease, software and oncological markets.
In addition to his operational leadership, Mr. Rothberg has been responsible for and developed strategic business partnerships, infrastructure agreements, merger/acquisition agreements and international distribution agreements. He has successfully negotiated numerous contracts, technology licensing and business acquisition agreements. He has served as a board member for both publicly traded and privately held U.S. based companies and several foreign-based companies.
Mr. Rothberg also has extensive experience in the South Florida life science industry as a business development executive in the medical device, software and bio-pharmaceutical markets. He is presently on the Board of BioFlorida, the state’s life science trade industry group and serves as co-Chair of its southeast chapter.
Mr. Rothberg holds a Bachelor of Engineering in Chemical Engineering from Vanderbilt University and a Masters of Business Administration from Nova University.
